RVL Pharmaceuticals plc (RVLP) Tops Q2 EPS by 10c

RVL Pharmaceuticals plc (NASDAQ: RVLP) reported Q2 EPS of ($0.14), $0.10 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $8.4 million versus the consensus estimate of $8.72 million.

For earnings history and earnings-related data on RVL Pharmaceuticals plc (RVLP) click here.

You May Also Be Interested In

• Citigroup (C) Tops Q2 EPS by 42c
• Cantor Fitzgerald: MKS Instruments (MKSI) 'Remains Our Top Pick Within the SMID Cap Space'
• Virtu Financial posts Q2 2026 preliminary results, seeks $400M loan